Construction of the 15,000-square-foot facility infrastructure, which will include five new packaging suites and a new quality control laboratory, is due to be completed in February 2019, with installation and commissioning of new equipment to be phased throughout the year.

This will include both a semi-automated and fully-automated top loading cartoner, an accessorized combination syringe assembly machine, an automated auto-injector assembly machine, and two semi-automatic visual inspection machines.

The expansion augments existing capabilities, meeting the necessary flexibility requirements for current and future market demand, and will provide customers with faster, automated packaging solutions.

Additionally, the auto-injector and accessorized syringe assembly machines will help address market growth of these delivery technologies driven by a desire for improved patient compliance and safety for health care providers who administer injections. It is estimated that the expansion will create 36 new jobs at the site, which Catalent acquired in 2017.

“The packaging expansion will further enhance our comprehensive end-to-end offering for clinical and commercial customers, complementing the services that Catalent Biologics provides, including cell line development, biologics analytical, biomanufacturing, antibody-drug conjugate development, drug product fill/finish, and clinical supply services.” commented Cory Lewis, Vice President and General Manager of the Catalent Biologics Drug Product business.

The Bloomington site recently achieved regulatory approval for a twentieth commercial product, and has deep expertise in sterile formulation and extensive biomanufacturing and drug product fill/finish capacity across liquid and lyophilized vials, prefilled syringes, and cartridges.

"All rights reserved except agreement written by Emballage Digest or mention of the magazine''